Plant Health Care Positive Developments with Harpin ab in sugarcane in Brazil

Chris Richards, Executive Chairman and Interim CEO of Plant Health Care, noted: “Grower reaction to demonstration trials of H2Copla has been very positive. Growers have already treated some 20,000 Ha of sugarcane with the product. The indication that just one customer (Furlan) plans to use H2Copla on 20,000 Ha next year, points to significant revenue growth in 2019. Demand for Harpin ab in Brazil is expected to reach at least $0.8m in 2018.”

Plant Health Care Plc (LON:PHC), a leading provider of novel patent-protected biological products to global agriculture markets, today provided the following update on the launch of H2Copla (Harpin ab) in sugarcane in Brazil.

Highlights:

– H2Copla (Harpin ab) has been applied on some 20,000 hectares (Ha) of sugarcane since ‘soft launch’ in February 2018

– Average yield increases in excess of 20% are driving strong demand; early adopters plan to switch entirely to H2Copla for the next season

– Grower response to the results has been very positive

– Sales by PHC to Coplacana are expected to reach $0.8m in 2018, pointing to strong growth in 2019

As previously announced, Brazil sugarcane, with 10 million Ha planted, is an important target for Plant Health Care. The Company has been developing Harpin ab for use in this crop since 2016. Coplacana, a very large co-operative and the leading distributor of inputs for sugarcane, was appointed as distributor to launch Harpin ab under the brand name H2Copla. Following a ‘soft launch’ in February 2018, Coplacana has been carrying out extensive demonstration trials of the product; H2Copla has been applied on some 20,000 Ha to date by various growers.

Trials conducted on behalf of the Company in 2018 showed that single applications of a low dose (100 g per Ha), significantly increased the yield of sugarcane (10-29%). Moreover, it is possible that the life of the crop may be extended from five to six years, resulting in a material cost reduction for the grower, especially when sugar prices are low. Grower response to the results has been very positive.

Furthermore Usina Açucareira Furlan S/A (‘Furlan’), a large sugarcane producer located in the state of São Paulo, carried out field trials in 2018, as part of the soft launch by Coplacana, which delivered an average 23% yield increase from H2Copla applicatons. Furlan now plans to use H2Copla on their entire area next season.

Gilmar Rorigues de Morais, Agriculture Department Manager at Furlan, said “We are excited about the yield increases from this year’s trials and plan to use H2Copla on all of our 20,000 Ha for the 2019 growing season.”

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Plant Health Care Plc

    More articles like this

    Plant Health Care Plc

    Plant Health Care appoint new Board directors

    Plant Health Care (LON:PHC) has announced three new Board appointments with effect from 1st November 2019. Mr Guy van Zwanenberg FCA will join the PHC Board as a Non-executive Director. He will take over as Chair of the

    Plant Health Care Plc

    Plant Health Care Progress with PREtec field trials in Brazil

    Plant Health Care (LON:PHC), a leading provider of novel patent-protected biological products to global agriculture markets, has today provided the following update in relation to the 2018/19 field trials of the PREtec peptide PHC279 for the

    Plant Health Care Plc

    Plant Health Group plc New Distribution Agreement for Harpin αß

    Plant Health Care plc (LON:PHC), a leading provider of novel patent-protected biological products to global agriculture markets, today announced a new distribution agreement with Wilbur-Ellis Company LLC, a leading U.S. agriculture distributor, for exclusive access to

    Path Investments Plc

    Path Investments plc Update on Heads of Agreement

    Path Investments plc (LON: PATH) today provided an update regarding the Heads of Agreement with ARC Marlborough Pty Limited (“ARC”) in relation to the proposed acquisition of ARC by the Company (the “Proposed Transaction”) announced on

    Plant Health Care Plc

    Plant Health Care Made exciting progress in 2018

    Chris Richards, Plant Health Care Interim CEO, commented: “Plant Health Care continued to make exciting progress in 2018, in spite of recently announced set-backs. The launch of our new corn product in the US holds great

    Plant Health Care Plc

    Plant Health Care Plc ProAct® Wins Top Industry Award

    Chris Richards, Executive Chairman and Interim CEO of Plant Health Care noted: “This award is recognition that Plant Health Care, as a science-based company, can bring new benefits to growers with low toxicity, biological products. We

    Plant Health Care Plc

    Plant Health Care to present at Mello London

    Plant Health Care (LON: PHC), a leading provider of novel patent-protected biological products to global agriculture markets, today announced that the Company will be presenting at the Mello London investor conference on Tuesday 27 November 2018